Non-Surgical Weight Loss Options That Have Real Trials Behind Them
Lifestyle, drugs and endoscopy each lose weight at different rates, and the numbers are good but young, like a promising intern.

In the MERIT trial, the people assigned to lifestyle modification lost 0.8% of their body weight in a year. That is not a typo, and it is not a scandal. It is the control group doing its job, which is to stand next to the treatment and make it look tall. The people in the same trial who got an endoscopic sleeve gastroplasty lost 13.6%.
So here is the plain answer. The non surgical weight loss options with randomized trials behind them sort into three tiers. Lifestyle programs produce modest losses, in the neighborhood of the 5% mark that behavioral studies use as their bar for success. Medications produce the biggest numbers in this group: 16.0% for semaglutide in STEP 3 and 22.5% for the top dose of tirzepatide in SURMOUNT-1. Endoscopic procedures sit between the two, with ESG at 13.6% after a year and intragastric balloons a step below it, with results that one review calls typically temporary.
What the lifestyle tier of non surgical weight loss actually shows
Lifestyle programs (diet, exercise, coaching, weigh-ins, the whole apparatus) show up in the trials here mostly as the comparison arm. They are rarely the thing being tested (which is an odd career for a treatment). In STEP 3, everybody got intensive behavioral therapy, and the placebo group, which got the therapy plus a dummy injection, lost 5.7% at 68 weeks. In MERIT the lifestyle arm lost 0.8% at 52 weeks.
I feel like the lifestyle arm is the Washington Generals of medicine. It shows up to every game. It plays honestly. It loses on schedule, because losing is the role it was cast in. Somewhere a trial coordinator is saying, very kindly, “So the good news is you’re in the study, and the other news is you’re in the group that gets the pamphlet.”
On its own terms, the lifestyle tier is measured against a small target. A meta-analysis of the WW program used 5% weight loss as its threshold and found that Non-Hispanic Black participants were significantly less likely than Non-Hispanic White participants to reach it at 3, 6 and 12 months. So the bar is 5%, and the bar is not cleared evenly. Why that gap exists is not settled by the facts here.
Medication: the biggest trials and the biggest numbers
The drug tier is where the large, placebo-controlled trials live. In STEP 3, semaglutide 2.4 mg plus behavioral therapy produced 16.0% mean weight loss against 5.7% for placebo plus therapy, from an average starting weight of 105.8 kilograms. The drug’s own contribution is the gap, a bit over ten points, stacked on top of the lifestyle program everyone already had.
In SURMOUNT-1, tirzepatide 15 mg produced 22.5% mean weight loss, and 36.2% of people at that dose lost at least a quarter of their body weight. A network meta-analysis of 23 randomized trials covering 14,293 participants put tirzepatide at 10 or 15 mg at 21.3% total weight loss and sleeve gastrectomy at 21.1%, and called them “statistically equivalent.” That is true, and it is worth reading the intervals: the sleeve estimate runs from 14.2% to 28.0%, which is wide enough to park a truck in. Hard to tell apart is not the same as identical. (The sleeve-versus-drug comparison has its own article on this site, which I will not relitigate here.)
Outside trials, things get noisier. A real-world cohort from Türkiye found adjusted weight loss at month 3 of 8.38% for semaglutide and 11.52% for tirzepatide, a real difference. By month 6 the gap had shrunk to 14.40% versus 15.06% and was no longer significant, though the authors note that “only 4 tirzepatide-treated patients had measurements within the month 6 visit window.” Four is a number of patients. It is not a large one (it is, for instance, smaller than most dinner parties).
Endoscopy: stitches, balloons and a unit problem
The endoscopic tier rests mostly on MERIT, a multicenter randomized trial of ESG against lifestyle modification. Its primary endpoint was excess weight loss at 52 weeks, with excess weight defined as “weight above the ideal for a BMI of 25 kg/m².” Translated: your excess weight is whatever you weigh minus what you would weigh if you sat exactly at the top of the normal range.
This matters, and I mean that with some ceremony. Let the record reflect that MERIT reports 49.2% excess weight loss and 13.6% total body weight loss, that these two figures describe the same people at the same moment, and that neither is wrong. They are fractions with different denominators. The first number divides by the weight you were supposed to lose; the second divides by all of you.
To be clear, this is invented, but follow it out. Imagine a clinic that decides the ideal BMI is 31 instead of 25. A patient at BMI 32 who loses a few pounds now has 100% excess weight loss. Set the ideal at the patient’s current weight and every patient is cured at intake, with excess weight loss of infinity percent, a result no journal would print and no marketing department would refuse. The real trials use 25, which is the point of writing the definition down.
On durability, MERIT found that 68% of ESG patients kept at least 25% excess weight loss at 104 weeks. The protocol also allowed that control patients who did not lose enough were offered crossover to ESG at 52 weeks, and that “ESG participants were offered retightening,” which in context is a suturing procedure and out of context sounds like an amenity at a discreet spa. A review of the broader literature puts ESG at 13% to 16% total weight loss at 12 months, sustained up to 3 years.
Balloons sit below ESG. A network meta-analysis of randomized trials ranked ESG first for weight loss at 12 months, ahead of the Spatz3 and Orbera balloons. A narrative review summarizing 2023 to 2025 data put balloons at roughly 10% to 15% total weight loss with “typically temporary results after removal.” The balloon gets its own article here, and that phrase is most of it.
Three ways to read the evidence tiers
There are, roughly, three ways to read this ladder.
The first is the obvious one: the tiers rank how well things work. Lifestyle gets you around 5%, balloons maybe 10% to 15%, ESG around 14%, semaglutide 16%, tirzepatide over 20%. Stuff higher on the list removes more weight. Fine. That reading is not dumb, and it is mostly what the numbers say.
The second is that the tiers also rank how well things have been tested, which is a different question. Drug trials enroll thousands of people against placebo, because a drug company with a product to approve has reason to pay for that. ESG has one big randomized trial against a lifestyle arm, reported in a unit that needs a footnote. Lifestyle, on the other hand, gets tested constantly, but usually as somebody else’s baseline. (Much of my job is converting excess weight loss into total weight loss in my head, and I am not good at it.) So part of the ladder is efficacy, and part is the budget for proving efficacy, and the two are tangled.
The third reading is the least comfortable, i suppose. Every number above is attached to a stopwatch: 52 weeks, 68 weeks, 104 weeks. Balloons are explicitly temporary. The same narrative review that gave balloons 10% to 15% gave GLP-1 drugs about the same, around 10% to 15%, well under the 16% and 22.5% from the trials. What happens to non-surgical losses over a decade is not settled by anything here. Weird, then, that the surgery tier has the long data: the LABS study found 28.4% weight loss seven years after bypass, and a Geisinger study found bypass patients holding at 23% between 10 and 20 years out.
Anyway, the point is that the ladder is real, and it is also short. The non-surgical numbers are good. They are also young.
Sources
- Tirzepatide Once Weekly for the Treatment of Obesity
- Lilly's SURMOUNT-1 results published in The New ...
- Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial
- Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review
- Effectiveness of a behavioral weight management intervention by race, ethnicity, income, and education: a meta-analysis
- Body Weight Changes and Exploratory Metabolic Outcomes During Semaglutide and Tirzepatide Treatment: A Real-World Longitudinal Cohort Study from Türkiye
- Shaping the Future of Restrictive Bariatric Surgery: Clinical, Economic, and Long-Term Perspectives on Endoscopic and Laparoscopic Sleeve
- Seven-Year Weight Trajectories and Health Outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) Study
- News Details
- Comparative effectiveness of balloons, adjustable balloons, and endoscopic sleeve gastroplasty: a network meta-analysis of randomized trials
- GLP-1 medications versus surgery and balloon: evaluating cost-benefit in weight loss
- Roux-en-Y gastric bypass results in long-term durable weight loss and diabetes remission: a single center, > 15 year outcomes
- New Study Shows Long-term Effectiveness of Gastric Bypass in Treating Type 2 Diabetes and Obesity - American Society for Metabolic and Bariatric Surgery
Bariatric Alt explains published research. It is not medical advice, and it never recommends a surgeon, a clinic, a dose or a product. Talk to a clinician about which option fits you.